Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement

Saved in:
Bibliographic Details
Published in:European journal of heart failure 2017, Vol.19 (Suppl: 1), p.19
Main Authors: Adams, D., Coelho, T., Conceicao, I., Cruz, M. Waddington, Schmidt, H., Buades, J., Campistol, J., Pouget, J., Berk, J. L., Ziyadeh, N., Partisano, A. M., Sweetser, M., Chen, J., Gollob, J., Suhr, Ole
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:1879-0844
1388-9842